Articles related to CAR-T THERAPY
Myeloma Patients Who Relapse After CAR T-Cell Therapy Have Options
With the initial attempt at salvage therapy, the median PFS was 3.5 months. The objective response rate (ORR) for these patients was 43.4%, with strict complete responses (9.2%), very good partial responses (11.8%), and partial responses (22.4%) all being achieved by patients. A significantly longer median OS of 29.9 months compared to 14.6 months for patients who did not achieve an objective response was associated with achieving a partial response or better with the first line of salvage therapy.
Hematology November 14th 2022
CAR T-Cell Therapy for Relapsed/Refractory Non-Hodgkin’s Lymphoma (NHL): A Comprehensive Review
CAR T-cell therapy has changed the treatment paradigm for relapsed/refractory aggressive B-cell NHL. The approach has seen strong response rates and durable remission in those whose disease has progressed despite multiple prior treatments. This review outlines current indications for CAR T-cell therapy, major toxicities, novel CARs under investigation, CARs for various hematologic malignancies, and future directions.
Oncology, Medical May 25th 2022
Phase 1 trial early data show encouraging clinical activity for an investigational CAR T-cell therapy alone or in combination with an amplifying mRNA vaccine for patients with solid tumors.
Phase 1 trial using an autologous CAR-T cell therapy that targets the oncofetal antigen Claudin-6 (CLDN6) — and CARVac (BioNTech), a CLDN6-encoding mRNA-based vaccine designed to enhance CAR T-cell activity. Data show encouraging clinical activity for an investigational CAR T-cell therapy alone or in combination with an amplifying mRNA vaccine for patients with solid tumors.
Oncology, Medical May 11th 2022
Decade-Long CLL Remission After CAR T-Cell Therapy Reported
Researchers reported the finding—the longest known CLL remission after CAR T-cell therapy—in Nature. The patients received an infusion of genetically engineered autologous T cells as part of a phase 1 clinical trial in 2010.
Oncology, Medical March 29th 2022
Autologous and Allogeneic CAR T-Cell Therapies: Spotlighting the “Brain-to-Vein” Time
Matthew Lunning, DO, Associate Vice Chair of Research at the University of Nebraska Medical Center, reviews treatment implications of emerging research in CAR T-cell therapy for a variety of lymphomas subtypes, and discusses newer study outcomes, limitations to current CAR-T cell products, the state of allogenic CAR-T cell therapy, and key elements to consider when selecting therapy for a given patient.
Internal Medicine March 15th 2022
Evolving Management of Patients with Double-Hit Lymphoma
Double-hit lymphoma presents as both aggressive, systematic disease with extra-nodal involvement and, apparently, as low-stage, less clinically aggressive disease. Since R-CHOP is much less effective in double-hit lymphoma, options such as CAR-T as well as novel drugs targeting cell-surface markers are being investigated. This interview with Dr. Ann S. LaCasce of Dana Farber summarizes current understanding and approaches to double-hit lymphoma.
Internal Medicine March 1st 2022